American Society for Radiation Oncology Annual Meeting (ASTRO)

This video reviews outcomes among breast cancer patients in the United States who refused recommended therapy for their cancer.

This video highlights 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.

This video reviews long-term results of the NRG Oncology RTOG 0915 trial, a randomized phase II study that compared stereotactic body radiation therapy delivered in one fraction vs four fractions for stage I peripheral non–small-cell lung cancer patients with unresectable disease.

This video reviews 4-year quality-of-life results from a prospective, population-based study that looked at prostate cancer patients who selected either active surveillance, radical prostatectomy, or external-beam radiation.

This video highlights a new study that found that markers of immune response in prostate cancer may be able to predict patients’ response to radiation therapy, likelihood of recurrence, and survival.

This video highlights studies on advanced lung cancer with practice-changing potential presented at the 2017 ASTRO Annual Meeting.

This video highlights potentially practice-changing studies on genitourinary cancers presented at the 2017 ASTRO Annual Meeting.

This video highlights studies on HPV-positive head and neck cancer presented at the 2017 ASTRO Annual Meeting.

This video reviews results of a phase III trial that compared pelvic radiation therapy vs vaginal cuff brachytherapy plus chemotherapy in patients with early-stage, high-risk endometrial cancer.

Patients who reported severe distress were more likely to miss radiation therapy appointments and be hospitalized during the course of their therapy compared with patients with lower distress scores, according to the results of a study presented at the ASTRO Annual Meeting in San Diego.

Four in 10 patients with cancer being treated at an urban cancer center had depression, the majority of which was previously undiagnosed, according to the results of a study presented at the ASTRO Annual Meeting.

Undergoing SBRT prior to starting maintenance chemotherapy significantly improved progression-free survival in patients with limited metastatic non–small-cell lung cancer, according to the results of a phase II study presented at the ASTRO Annual Meeting.